The company states: “Artelo Biosciences (ARTL) announced that Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, will be presenting at the 7th Cannabinoid-Derived Drug Development Summit. The event will take place November 18-20, 2024, at the Wyndham Beacon Hill Hotel in Boston, MA. Key data from Artelo’s development programs will be highlighted in three separate sessions titled: Fatty Acid-Binding Protein 5 Inhibitors as Novel Therapeutics (featuring ART26.12); ART27.13: A Peripherally Selective CB1/CB2 Agonist for Cancer Cachexia; ART12.11: A Novel Cannabidiol Cocrystal Demonstrating a Pharmacokinetic Profile Comparable to Epidiolex(R) in Rats.”
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARTL:
- Artelo Biosciences Reports Q3 2024 Financials and Progress
- Artelo Biosciences announces new data on novel non-opioid treatment for OA pain
- Artelo Biosciences reports Q3 EPS (35c), consensus (46c)
- Artelo Biosciences announces acceptance of ART26.12 into NIH PSPP program
- Is ARTL a Buy, Before Earnings?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
